OrthoSera closes Series B financing round
hypACT serum therapy for the regeneration of osteoarthritic bone and cartilage is entering clinical development
Austrian OrthoSera GmbH, an orthobiologics company developing serum-based solutions for musculoskeletal indications announces the closure of their Series B financing. All Series A investors teamed up with a family office and jointly invested in OrthoSera in order to fund clinical studies with hypACTTM.
“We are very pleased with the continued support of our lead investor FastVentures, who together with Euroventures and Futurmed were instrumental in closing this oversubscribed financing round“ says Björn Ehring, CFO of OrthoSera.
Successful launch of BoneAlbuminTM in 2015
After the successful launch of BoneAlbuminTM in 2015, OrthoSera is introducing its next innovative serum-based product to the market. hypACTTM, a novel hyperacute serum has shown very positive effects compared to PRP and other blood derivatives in ex vivo osteoarthritic human tissues. This patent-covered serum extraction is currently being clinically administered in Europe with OrthoSera’s CE-marked autologous hypACT InjectTM device.
The initial indication of hypACTTM is regeneration of articular tissues, including cartilage and bone in the knee for the treatment of osteoarthritis patients. Clinical data is being gathered through a number of key opinion leaders in the field. „Serum therapies are on the rise and will be the next wave of orthobiologics in the coming years“, says Zsombor Lacza, Founder and CEO.
Financial details were not mentioned.